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BACKGROUND: There is growing interest in using C-
reactive protein (CRP) levels to help select patients for
lipid lowering therapy—although this practice is not yet
supported by evidence of benefit in a randomized trial.
OBJECTIVE: To estimate the number of Americans
potentially affected if a CRP criteria were adopted as
an additional indication for lipid lowering therapy. To
provide context, we also determined how well current
lipid lowering guidelines are being implemented.
METHODS: We analyzed nationally representative data
to determine how many Americans age 35 and older
meet current National Cholesterol Education Program
(NCEP) treatment criteria (a combination of risk factors
and their Framingham risk score). We then determined
how many of the remaining individuals would meet
criteria for treatment using 2 different CRP-based
strategies: (1) narrow: treat individuals at intermediate
risk (i.e., 2 or more risk factors and an estimated 10–
20% risk of coronary artery disease over the next
10 years) with CRP>3 mg/L and (2) broad: treat all
individuals with CRP>3 mg/L.
DATA SOURCE: Analyses are based on the 2,778
individuals participating in the 1999–2002 National
Health and Nutrition Examination Survey with com-
plete data on cardiac risk factors, fasting lipid levels,
CRP, and use of lipid lowering agents.
MAIN MEASURES: The estimated number and propor-
tion of American adults meeting NCEP criteria who take
lipid-lowering drugs, and the additional number who
would be eligible based on CRP testing.
RESULTS: About 53 of the 153 million Americans aged
35 and older meet current NCEP criteria (that do not
involve CRP) for lipid-lowering treatment. Sixty-five
percent, however, are not currently being treated, even
among those at highest risk (i.e., patients with estab-
lished heart disease or its risk equivalent)—62% are
untreated. Adopting the narrow and broad CRP strate-
gies would make an additional 2.1 and 25.3 million
Americans eligible for treatment, respectively. The latter
strategy would make over half the adults age 35 and
older eligible for lipid-lowering therapy, with most of the
additionally eligible (57%) coming from the lowest NCEP
heart risk category (i.e., 0–1 risk factors).
CONCLUSION: There is substantial underuse of lipid
lowering therapy for American adults at high risk for
coronary disease. Rather than adopting CRP-based
strategies, which would make millions more lower risk
patients eligible for treatment (and for whom treatment
benefit has not yet been demonstrated in a randomized
trial), we should ensure the treatment of currently
defined high-risk patients for whom the benefit of
therapy is established.
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INTRODUCTION
In November 2002, a study
1 suggesting that high sensitivity C-
reactive protein (CRP) level might be a stronger predictor of
cardiovascular events than LDL cholesterol received a great
deal of attention in the media(including the cover story in US
News and World Reports) and in the medical community.
2–4
Responding to growing interest in CRP testing, and recognizing
that its widespread use might dramatically affect the number
of people labeled “at risk” for heart disease, the Centers for
Disease Control and Prevention and the American Heart
Association convened a consensus panel to develop evidence-
based guidelines for the role of CRP in cardiovascular risk
assessment. While the panel did not support universal testing,
it did acknowledge that CRP might help physicians decide
whether or not to initiate lipid-lowering treatment (as primary
prevention) for some individuals at moderately elevated risk
based on traditional factors and their Framingham risk score.
5
Professional and public interest in the use of CRP as a
screening test for heart risk has only grown with the publica-
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197tion of two observational analyses, which found that a
reduction of CRP levels to less than 2 mg/L was associated
with improved clinical
6 and intravascular ultrasound
7 out-
comes in patients with established heart disease. The incre-
mental value of CRP testing above conventional factors (i.e.,
age, smoking, hypertension, and lipids) in predicting heart risk
remains controversial
8–10, and there are still no randomized
trials demonstrating that cholesterol-lowering treatment ben-
efits those whose only indication for treatment is elevated CRP.
Nonetheless, many clinicians use CRP to guide treatment
decisions for patients without heart disease.
11 In fact, CRP
testing for cardiovascular risk assessment has become so
common that it now has its own billing code—CPT 86141.
12
The number of such tests performed in the Medicare popula-
tion tripled (from 145,000 to 454,000) between 2002 and
2004, the only years for which data are available (personal
communication, Daniel Gottlieb, Dartmouth Atlas Group,
Dartmouth Medical School). Some of the popularity of CRP
testing may stem from aggressive marketing by high-profile
proponents of the test who also have a financial stake in its
use. For example, the CRPHealth.com web site highlights that
President George W. Bush, a man at low risk for cardiovascular
disease, has CRP as part of his annual executive physical
exam.
2,13
In this paper, we seek to understand some of the con-
sequences of using CRP as an indication for lipid-lowering
treatment. Specifically, we estimate how many Americans who
do not meet the current criteria for lipid-lowering therapy
would become eligible solely because of an elevated CRP level.
To put these numbers in context, we also estimated how many
people are being treated under current National Cholesterol
Education Program (NCEP) guidelines.
METHODS
Overview
Using a nationally representative sample from the National
Health and Nutrition Examination Survey
14 (NHANES), our
analysis involved the following 2 steps. First, we used the
NCEP
15 algorithm to estimate how many adults are currently
eligible for treatment by NCEP criteria. Second, we estimated
the additional number who would become eligible if a CRP
strategy were adopted.
Data Source
All data are from the 1999–2002 NHANES survey.
14 NHANES
is conducted by the National Center for Health Statistics,
Centers for Disease Control and Prevention to assess the
health and nutritional status of the civilian, noninstitutional-
ized population of the United States. NHANES surveys, con-
ducted periodically since the 1970s, and annually since 1999,
involve household interviews and standardized medical
examinations including a variety of blood tests such as high-
sensitivity CRP and fasting lipid profiles. Since 1999, approx-
imately 7,000 people have participated in NHANES each year.
The complex sampling design, data collection methods, re-
sponse rates (approximately 80% each year), and weighting
approach are described elsewhere.
16–18 As suggested in the
NHANES documentation, we combined data files for years
1999–2002 (the most recent years with complete data needed
for analyses) to create a single analytic file (N=21,004 persons
of all ages).
16
Approximately one third of sample adults were randomly
selected to undergo the morning laboratory examination, at
which fasting lipid profiles and CRP levels were drawn. We
analyzed the 2,778 individua l sa g e d3 5a n do l d e rw i t h
complete data on cardiac risk factors [to assign them to a
coronary heart disease (CHD) risk category and to calculate
their Framingham score], fasting lipids (to determine whether
they meet the NCEP LDL treatment threshold), CRP level, and
current use of lipid-lowering agents. The characteristics of the
NHANES participants in our analysis appear in Table 1.
Currently Eligible by NCEP Criteria
Identify treatment status. The NCEP uses a combination of
fasting LDL cholesterol level and estimated CHD risk to
determine recommendations for lipid-lowering therapy.
15
Because treatment alters these parameters, our first step was
to distinguish treated and untreated individuals. Treatment
status was determined as follows. During the NHANES in-
home interview, survey participants were asked if they have
taken a medication in the past month for which they needed a
prescription. Those who answered “yes” were asked to show
the interviewer the bottles of all the medicines and these were
entered into the database. We categorized people as currently
Table 1. Characteristics of NHANES participants 35 and older with
complete data
Characteristics NHANES
participants
(n=2,778)
Weighted
% (SE)
Age, y
35–49 999 47% (2%)
50–64 847 31% (1%)
65–79 651 17% (0.8%)
≥80 281 5% (0.4%)
Sex
Female 1,433 53% (0.8%)
Male 1,345 47% (0.8%)
Race/ethnicity
White 1,483 76% (2%)
Hispanic 746 11% (2%)
Black 475 10% (1%)
Other 74 4% (0.8%)
Education
<High school 946 21% (1%)
High school 584 25% (1%)
More than high school 1,243 54% (2%)
CHD or risk equivalents
Known CHD 289 9% (0.7%)
Diabetes mellitus 240 8% (0.7%)
Prior stroke 99 3% (0.4%)
CHD risk factors
Current smoker 563 22% (1%)
Hypertension (BP>140/90 or
taking antihypertensive meds)
1,292 40% (1%)
Low HDL (HDL<40 mg/dl) 584 21% (0.8%)
Family history of premature CHD
(before age 50)
247 11% (0.7%)
NHANES National Health and Nutrition Examination Survey, CHD
coronary heart disease.
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following lipid-lowering medications available at the time:
atorvastatin, cervistatin, fluvastatin, lovastatin, pravastatin,
simvastatin, cholestyramine, colestipol, fenofibrate, and
gemfibrozil.
Determine eligibility of the untreated. We used the NCEP’s3 -
step algorithm to determine whether untreated individuals
were currently eligible for treatment (Fig. 1).
15 This process
begins with assigning people to a risk category. Individuals
who reported having CHD or diabetes mellitus were assigned
to the group “CHD or CHD equivalent.” While the NCEP also
counts symptomatic carotid artery disease, abdominal aortic
aneurysm, and peripheral arterial disease as CHD equivalents,
we were not able to do so since the relevant information was
not collected by NHANES. For the remaining individuals, the
next step was to determine how many CHD risk factors (e.g.,
age≥45 for men, age≥55 for women, cigarette smoking,
hypertension, low HDL, family history of premature CHD,
and age) were present. For those with 2 or more CHD risk
factors, we calculated the 10-year risk of myocardial infraction
or CHD death according to the Framingham scoring system, a
model which uses age, gender, total and HDL cholesterol,
smoking, blood pressure, and diabetes status to estimate
risk.
19 If the calculated risk was >20%, the individual was
assigned to the group “CHD (or equivalent);” if the calculated
risk was 10–20%, the individual was assigned to the group “≥2
risk factors, 10–20% risk;” if the calculated risk was lower than
10%, assignment was to “≥2 risk factors, <10% risk.” The
remaining individuals were assigned to the group “0–1 risk
factor.”
Untreated individuals were considered eligible for treatment
(according to the NCEP guidelines) if their LDL level exceeded
the CHD risk category-specific threshold: LDL≥100 mg/dL for
individuals with CHD or CHD equivalent; ≥130 mg/dL for
individuals with multiple risk factors and 10–20% 10-year
risk; ≥160 mg/dL for multiple risk factors and <10% 10-year
risk; and ≥190 mg/dL for 0–1 risk factors.
15
Determine eligibility of the treated. We used the same approach
for treated individuals except that we had to make
assumptions about risk factors which could plausibly be
affected by lipid-lowering therapy: HDL and total cholesterol
levels. If we did not account for treatment effects we would
tend to misclassify individuals into falsely low-risk categories.
We therefore made conservative assumptions about
pretreatment values: that people take their medication
regularly and that they experience the lipid effects observed
in studies published in the medical literature (i.e., average
HDL raised by 3 mg/dL and average total cholesterol lowered
by 42%
15,20. Correcting the HDL and total cholesterol levels
moved <1% of treated individuals in the study sample into
higher risk categories.
Finally, we also made the assumption that all treatments
were appropriate based on the NECP criteria. This assumption
has 2 conservative effects. First, it biases upward our estimate
of the proportion of persons eligible for lipid-lowering therapy
who are being treated (i.e., we overestimate compliance with
recommendations). Second, it biases our estimate of the
additional number of persons eligible for treatment by CRP
downward because we only consider the effect of the CRP
strategies on untreated individuals.
Does the individual have known CHD 
(or its risk equivalent)?
Symptomatic carotid artery disease
Abdominal aortic aneurysm
Peripheral artery disease
Diabetes mellitus
How many CHD risk factors?
Older age (men  age > 45; women age > 55)
Cigarette smokiing
Hypertension (BP>140/90 or
    taking antihypertensive medications)
Low HDL cholesterol (<40 mg/dL)
Family history of premature CHD
    (first degree male relative age<55; 
     first degree female relative age < 65)
Calculate the individual’s 
10-year risk of having or
dying from heart attack
(using Framingham score)
Yes
CHD
or equivalent
(n=30,917,000)
> 2 Risk factors
10-20%  risk
(n=21,392,000)
0-1 Risk factor
(n=69,718,000)
> 2 Risk factors
<10%  risk
(n=31,084,000)
Risk categories
No
< 1
> 1
10-20%
< 10%
> 20%
LDL level  for 
treatment eligibility
> 100 mg/dL
> 130 mg/dL
> 190 mg/dL
> 160 mg/dL
Figure 1. National Cholesterol Program’s Adult Treatment Panel (ATPIII) algorithm and estimated number of American adults in each risk
category.
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We then determined how many additional people (i.e., not
meeting the NCEP criteria) would become eligible for lipid-
lowering therapy based on an elevated CRP value. We consid-
ered 2 different CRP treatment strategies: (1) narrow CRP
strategy
5—treat individuals at moderate risk (i.e., 2 or more
risk factors and an estimated 10–20% risk of coronary artery
disease over the next 10 years) with CRP>3 mg/L; and (2) broad
CRP strategy
21–23—treat all individuals with CRP>3 mg/L.
Rationale for CRP Strategies
The narrow strategy is based on the American Heart Associa-
tion/Centers for Disease Control statement that CRP testing
“may be used at the discretion of the physician in patients
judged by global risk assessment to be at intermediate risk
(10% to 20% risk of CHD per 10 years) for cardiovascular
disease,” using a 3-mg/L threshold for treatment.
24 The broad
strategy is based on published recommendations by propo-
nents of the test
25 and one that is, anecdotally, accepted by
some practicing physicians.
2,11 We restricted all analyses to
persons age 35 and older because this is the age at which
proponents suggest CRP first be measured.
25 Under both strat-
egies, we excluded individuals with a CRP level >10 mg/L, as
most experts believe a level this high cannot be used to predict
heart disease and instead suggests the presence of a major
infection, trauma, or chronic inflammatory disease.
25
Analysis
All NHANES analyses incorporated the morning sample
weights (WTSAF4YR) to account for differential probability of
selection across subjects and for nonresponse (this weight was
used because some blood tests required fasting) and design
effects variables (SDMVPSU and SDMVSTRA) in order to
account for the survey’s complex, multistage sampling strategy
when calculating standard errors.
18 We used the SVY series of
commands in STATA 9.0 (College Station, TX) designed for
analyzing complex survey designs such as NHANES. To obtain
estimated counts of Americans in each category, we multiplied
the nationally representative proportions from NHANES by the
most recent population projection (2005) of adults aged 35 and
older (153 million) from the US Census Bureau.
26
RESULTS
Currently Eligible by NCEP Criteria
We estimate that 53 of the 153 million Americans aged 35 and
older meet current NCEP criteria (that do not involve CRP) for
lipid-lowering treatment (Table 2). Among the 53 million
eligible, 18.6 million currently report taking a lipid-lowering
medication and 34.1 million meet the NCEP criteria but are
currently untreated. Overall, 65% of the people meeting
current criteria are not being treated with lipid-lowering
medications. Figure 2 shows how this proportion varied by
risk category. For example, 42% of those meeting criteria in the
lowest risk category (0–1 risk factor) were not being treated,
while 62% of the highest risk patients—those with CHD or its
risk equivalent—were also untreated (P<0.01).
Additional Eligible by CRP
Adopting a CRP-based strategy for lipid-lowering therapy
would increase the number of Americans eligible for treatment,
but the impact varies dramatically depending on which
strategy is adopted. Adopting the narrow CRP strategy—
treating individuals at intermediate risk (i.e., 2 or more risk
factors and a calculated 10-year risk of coronary disease of 10–
20%) if their CRP level exceeded 3 mg/L—would increase the
number of adults eligible for treatment by 2.1 million (Fig. 3).
Under the broad CRP strategy, treating individuals whose CRP
exceeded 3 mg/L regardless of whether they meet NCEP
criteria increases the number eligible for treatment by 25.3
million, making over half the adults aged 35 and older eligible
for lipid-lowering therapy.
Who Would Be Affected by a CRP Treatment
Strategy?
By definition, the narrow CRP strategy can only affect individ-
uals at moderate predicted risk for CHD. In contrast, the broad
strategies largely affect individuals at low risk: 57% of adults
who become eligible for treatment only because of an elevated
CRP level are in the lowest CHD risk category (0–1 risk factor).
DISCUSSION
Our study has two major findings. First, the majority of adults
currently recommended for lipid-lowering therapy remain
untreated: almost two-thirds of Americans at high risk for a
myocardial infarction or CHD death are not taking lipid-
lowering medications. Second, adding a CRP strategy to
current cholesterol-based criteria could have a profound
impact on the number of people considered for treatment.
While a narrowly focused use of CRP in those at moderate risk
of coronary events group would make 2.1 million people
Table 2. Number of adult Americans eligible for lipid-lowering treatment using current NCEP criteria and using 2 CRP strategies
NCEP risk category Currently eligible by NCEP Additional eligible by CRP
Treated Untreated CRP>3 mg/L with risk factors CRP>3 mg/L
CHD or risk equivalent 9,952,000 16,199,000 1,211,000
≥2 risk factors with 10–20% risk CHD 3,598,000 10,182,000 2,132,000 2,132,000
≥2 risk factors with <10% risk CHD 1,990,000 5,420,000 7,480,000
0–1 risk factor 3,108,000 2,297,000 14,524,000
Total 18,648,000 34,098,000 25,347,000
CRP C-reactive protein, NCEP National Cholesterol Education Program, CHD coronary heart disease.
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up to over 25 million people—the majority of whom are in the
lowest CHD risk category.
Our findings should be interpreted in light of several
limitations. First, there is some misclassification of individuals
into the National Cholesterol Education risk categories. Be-
cause the NHANES database does not have specific measures
of 3 of the CHD risk equivalents (cerebrovascular disease,
aortic aneurysm, or peripheral vascular disease), we may
underestimate the number of individuals in the highest risk
category. However, given the substantial overlap between these
unknown and known factors (e.g., CHD, diabetes mellitus, a
calculated risk of heart disease of greater than 20%), this
misclassification is likely to be small. Another source of
misclassification may result from using information that
depends on respondent recall of risk factor information (e.g.,
history of MI) or on a single laboratory measurement. However,
any consequent misclassification would be random and should
largely cancel out (e.g., for every spuriously high LDL there will
be a spuriously low one).
Second, we assumed that all individuals taking lipid-
lowering medications were treated appropriately. Some low-
risk patients, of course, receive lipid-lowering treatment even
though they do not meet the NCEP indication; such inappro-
priate treatment has, in fact, been documented by others.
27
Assuming that all patients were treated appropriately makes
our findings conservative: it minimizes both our estimate of
undertreatment and the number of people additionally eligible
for treatment using a CRP criterion.
It is also important to recognize that not all people eligible
for lipid-lowering treatment will require a lipid-lowering med-
ication. The NCEP guidelines suggest that individuals whose
LDL values exceed a given risk-category specific threshold
value undergo a trial of diet and exercise with repeated LDL
testing prior to initiating medications. Unfortunately, thera-
peutic lifestyle changes are not very effective at lowering LDL
and few of these patients achieve the NCEP goals without
medication.
28,29 Furthermore, there is mixed evidence about
the effect of lifestyle changes on CRP. CRP levels did not change
among female smokers randomized to exercise training (vs
health education), despite a demonstrated improvement in
fitness.
30 I nat r i a lo fm e na n dw o m e na th i g hr i s kf o r
cardiovascular disease (based on standard risk factors), CRP
levels did not change appreciably (over 3 months) among
participants randomized to either a low-fat diet or a Mediter-
ranean-style diet with mixed nuts; however, CRP levels did
drop by an average of 0.5 mg/L for participants randomized to
a Mediterranean diet with virgin olive oil.
31 Finally, a third trial
(n=120) found CRP levels decreased by an average of 0.8 mg/L
over 2 years among obese, premenopausal women without
>2 risk factors* 
  
10-20% 10-yr risk
0% 20% 40% 60% 80% 100%
0-1 risk factor*
CHD or 
equivalent
>2 risk factors 
  
<10% 10-yr risk
% Taking Lipid Lowering Treatment  
(among those currently eligible by NCEP)
NHANES 
participants
569
298
117
82
Figure 2. Proportion taking lipid-lowering treatment among those currently eligible by National Cholesterol Education Program criteria
(assuming that all current treatment is appropriate). Error bars indicate the 95% CI for each proportion. Asterisks mean that the difference in
the proportion taking lipid-lowering treatment was statistically significant between the “coronary heart disease (CHD) or equivalent group”
and the “≥2 risk factors (10–20% 10-year risk) group (38% vs 26%, P=0.02),” and between the “CHD or equivalent group” and the “0–1 risk
factor” group (38% vs 58%, P=0.009).
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intensive multidisciplinary program that included a Mediter-
ranean-style diet and increased physical activity (vs general
information about diet and exercise).
32 To see how our results
would be affected if the intensive diet/exercise intervention
were successfully implemented prior to lipid-lowering medica-
tions, we performed a sensitivity analysis. Under the most
optimistic assumptions—assuming long-term compliance with
the intensive diet and exercise program (outside the context of
a trial) and granting a full 1-mg/L decrease in CRP levels—the
narrow and broad CRP strategies would still make an addi-
tional 1.5 and 18 million Americans, respectively, eligible for
statins.
While it is possible that a CRP strategy will turn out to be
useful, there is currently no evidence from randomized trials
demonstrating that lipid-lowering treatment benefits those
whose only indication for treatment is elevated CRP. Such a
trial is now underway: in the Jupiter trial, patients with a CRP
level of 2 mg/L or greater and an LDL<130 mg/dL are being
randomized to receive rosuvastatin or placebo.
33 There is also
ongoing controversy about the value of CRP in cardiovascular
risk assessment. While some suggest it is valuable because
CRP predicted CHD risk independent of traditional risk
factors,
1 others argue that the marginal value of CRP in risk
prediction is quite limited.
9,10,34–36
Our finding that almost two thirds of the highest risk
individuals (i.e., those with CHD or CHD equivalent) are
untreated is in line with other published work.
27,37,38 Un-
fortunately, there is no reason to think that CRP testing will
do anything to ameliorate this problem: most of the patients
who become eligible for treatment solely on the basis of CRP
in fact face the lowest CHD risk. Instead, widespread adop-
tion of CRP testing has the potential to turn a very real
problem of undertreatment into one of overdiagnosis. For
example, if the CRP threshold of the Jupiter trial
33—2 mg/dL
(the approximate median value for US adults
39—were used,
we estimate that an additional 40 million Americans would
become eligible for treatment. Unless it is highly targeted,
CRP testing will identify few new high-risk patients but,
instead, millions of low-risk ones who consequently stand to
CHD or
equivalent
>2 risk factors
10-20% risk
>2 risk factors
<10% risk
0-1 risk 
factor
Cardiovascular risk categories Totals
Additional adults eligible for lipid lowering treatment
 
(millions)
8
12
16
20
24
28
4
0
Treat all with CRP > 3
Treat > 2 risk factors (10-20% risk) with CRP > 3 
2.1 2.1 2.1
1.2
7.5
14.5
25.3
Figure 3. Additional numbers of adults estimated to be eligible for lipid-lowering treatment using two C-reactive protein strategies.
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low-risk individuals will come at a cost. In addition to the
obvious economic cost, and adverse treatment effects, there is
another more subtle one: the energy going into the treatment
of low-risk patients may distract physicians from more closely
attending to the needs of those at high risk. Widespread CRP
testing, that is, has the potential to make a bad situation
worse.
In summary, depending on its precise nature, adding a CRP
strategy to current cholesterol-based criterion could have a
profound impact on the number of people considered for
treatment. Adding a broadly applied CRP strategy to current
cholesterol-based guidelines would make over half of the
adults aged 35 and older in the United States eligible for
lipid-lowering therapy. Before expanding treatment criteria to
include more low-risk patients—for whom treatment benefit is
not established—we should ensure the treatment of high-risk
patients where the benefit of therapy is clear.
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